Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... July 2, 2021 Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer January 18, 2022 Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with... December 14, 2021 NICE recommends pembrolizumab for 1,600 more people with breast cancer November 14, 2022 Load more HOT NEWS Can Artificial Intelligence–Driven Chatbots Correctly Answer Questions about Cancer? Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations Carriers of a Germline Pathogenic Variant in CDKN2A are at a... Combination Chemo Helps People with Leiomyosarcoma Live Longer
